Sublocade shot withdrawal is the cluster of symptoms that can appear as extended‑release buprenorphine levels decline between monthly injections or after stopping. Because the medicine releases from a small under‑skin depot over weeks, effects may surface later and build slowly. Ontario patients do best with a supervised plan—timing tweaks, a bridge to Suboxone, or transition to Methadone/Kadian.

By Brian Taylor • Last updated: July 12, 2026

Summary

Sublocade is once‑monthly buprenorphine that releases from a subcutaneous depot. Withdrawal can feel delayed and then build as levels wane. Our Ontario approach prioritizes symptom control and relapse prevention: dose‑timing adjustments, a short Suboxone bridge for flexibility, or a measured transition to Methadone/Kadian with mental health support.

• Understand why depot medications create a “slow‑fade” withdrawal profile.
• See a practical Ontario timeline and red‑flag symptoms to act on.
• Compare real options: stay on Sublocade, bridge to Suboxone, or transition to Methadone/Kadian.
• Access same‑day OAT review via our secure portal and coordinated referrals.

For background on Sublocade itself, see our Sublocade overview and how long it lasts in our duration guide.

What Is Sublocade Shot Withdrawal — and Why It Happens

Sublocade withdrawal refers to symptoms that emerge as extended‑release buprenorphine gradually declines between injections or after discontinuation. The medication sits in a small under‑skin depot, so levels fall slowly. Planning dose timing, bridges, or transitions minimizes discomfort and reduces relapse risk.

While no two timelines are identical, here’s what our teams in Barrie, Hamilton, and Toronto hear most:

• Late week 3–4: Light sleep, more yawning, new restlessness. Some describe a “flu‑ish” undercurrent.
• Weeks 4–6: Gut upset, body aches, sweats, and stronger drug thoughts—especially if work or family stress is high.
• After week 6: Physical symptoms fade; cravings may pulse without relapse‑prevention steps.

Patients stabilized on higher initiation doses often report a longer runway before any symptoms, then a slower taper. That’s consistent with depot behavior seen in sustained‑release systems and summarized in this formulation discussion. For patient‑friendly timing expectations, see our how‑long‑it‑lasts guide.

Symptoms to Watch For (and Which Ones Need Medical Attention)

Common Sublocade withdrawal symptoms: insomnia, anxiety, chills or sweats, stomach cramps, diarrhea, body aches, and cravings. Seek urgent help for severe vomiting, dehydration, chest pain, confusion, suicidal thoughts, or suspected overdose. Don’t wait—contact your OAT clinic or emergency services.

• Manageable at home (with check‑ins): Restlessness, sweating, yawning, runny nose, mild cramps/diarrhea, increased cravings.
• Escalating—call us: Insomnia spanning several nights, rising anxiety or low mood, cravings linked to specific triggers.
• Red flags—urgent care: Persistent vomiting/diarrhea, signs of dehydration, chest pain, confusion, or any overdose concerns.

Our nurses can often add non‑opioid comfort medicines and coaching the same day. If you plan to stop altogether, read our stopping Sublocade guide and arrange a review first.

Why Stopping Sublocade Without a Plan Is Risky

Abruptly stopping removes buprenorphine’s protective effect while tolerance declines, raising overdose risk if opioids are reintroduced. A supervised plan—timed shots, a Suboxone bridge, or a Methadone/Kadian transition—keeps pharmacologic protection in place while symptoms are actively managed.

We’ve found that planned transitions prevent two common pitfalls: underestimating cravings during life stress and overestimating tolerance after time off medication. If you’re even considering a stop, book a same‑day review through our portal or call—don’t wait for symptoms to snowball.

Prefer to stay on Sublocade? We can move the next injection earlier within clinical guidance and pair it with short‑term supports. See practical details in our prescription explainer.

Your Real Options in Ontario: Tapering, Switching, or Transitioning Care

For most stable Sublocade patients who want flexibility or anticipate schedule changes, we prefer a short Suboxone bridge. We recommend Methadone or Kadian when full‑agonist support fits better—such as prior limited response to buprenorphine or complex pain. Staying on Sublocade with timing tweaks suits patients otherwise doing well.

Side‑by‑side options to discuss with your clinician:

Our bias, based on outpatient experience across Ontario: if you’re otherwise stable on Sublocade but need more control over timing, a Suboxone bridge is usually the smoother move. We look to Methadone/Kadian when a full‑agonist track better matches your history or goals.

How Road To Recovery Supports Patients Through Sublocade Changes

Across Ontario, we offer same‑day OAT intake, judgment‑free visits, and coordinated psychiatry referrals (CAMH/OTN). Your plan can include injection timing, a Suboxone bridge, or transition to Methadone/Kadian—plus counseling, sleep support, and family resources to reduce relapse risk.

• Access pathways: Secure online intake; phone support; walk‑in at select clinics.
• Continuity: If you work in one city and live in another, we align appointments so your plan stays intact.
• Whole‑person care: We integrate mental health referrals and brief counseling in‑house or virtually.
• Follow‑ups that fit: Early‑morning or late‑day visits help avoid late‑cycle dips.

Local considerations for all over Ontario

• Winter and summer travel can affect dosing windows; pre‑book earlier follow‑ups if delays are likely.
• Shift work varies by city; we can align early or late appointments to prevent late‑cycle dips.
• Relocating within Ontario? Request a warm handoff so records and your OAT plan move with you.

FAQs About Sublocade Shot Withdrawal

Most questions center on timing, safety of switching, and what to do if a dose is late. The short answer: call your OAT clinic early. Timing tweaks, Suboxone bridges, or Methadone/Kadian transitions reduce symptoms and protect against relapse.